Early-onset pancreatic cancer patients benefit more from neoadjuvant chemotherapy and surgery Post author:admin Post published: August 7, 2025 Post category:uncategorized The incidence of early-onset pancreatic cancer (EOPC) is rising, yet optimal treatment strategies remain unclear. You Might Also Like Longevity science and public health must unite for aging populations May 20, 2026 INmune Bio establishes global commercialization framework for Ebstrocelâ„¢ through strategic agreement with Uniphar October 22, 2026 Does space travel impact the human reproductive system? January 22, 2024
INmune Bio establishes global commercialization framework for Ebstrocelâ„¢ through strategic agreement with Uniphar October 22, 2026